# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
ADMA Biologics (NASDAQ:ADMA) sees FY2026 sales of $500.000 million-$625.000 million vs $641.17 million analyst estimate.
ADMA Biologics (NASDAQ:ADMA) sees FY2025 sales of $500.000 million-$625.000 million vs $507.67 million analyst estimate.
ADMA Biologics (NASDAQ:ADMA) reported quarterly earnings of $0.14 per share which met the analyst consensus estimate. This is a...